Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    G1 Therapeutics Inc.

    NASDAQ: GTHX · Real-Time Price · USD
    7.16
    0.01 (0.14%)
    At close: Sep 17, 2024, 7:56 PM

    G1 Therapeutics Statistics

    Share Statistics

    G1 Therapeutics has 52.76M shares outstanding. The number of shares has increased by 0.91% in one year.

    Shares Outstanding

    n/a
    		 52.76M

    Shares Change (YoY)

    n/a
    		 0.91%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 38.21%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 98,073

    FTD / Avg. Volume

    n/a
    		 4.4%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -3.29 and the forward PE ratio is null. G1 Therapeutics's PEG ratio is 0.05.

    PE Ratio

    n/a
    		 -3.29

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 1.91

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 4.46

    P/FCF Ratio

    n/a
    		 -4.12

    PEG Ratio

    n/a
    		 0.05
    Financial Ratio History

    Enterprise Valuation

    G1 Therapeutics has an Enterprise Value (EV) of 182.68M.

    EV / Sales

    n/a
    		 2.21

    EV / EBITDA

    n/a
    		 -4.68

    EV / EBIT

    n/a
    		 -4.77

    EV / FCF

    n/a
    		 -4.77

    Financial Position

    The company has a current ratio of 3.87, with a Debt / Equity ratio of 1.46.

    Current Ratio

    n/a
    		 3.87

    Quick Ratio

    n/a
    		 3.45

    Debt / Equity

    n/a
    		 1.46

    Debt / EBITDA

    n/a
    		 -1.47

    Debt / FCF

    n/a
    		 -1.49

    Interest Coverage

    n/a
    		 -3.94

    Financial Efficiency

    Return on Equity is -135.55% and Return on Invested Capital is -48.62%.

    Return on Equity

    n/a
    		 -135.55%

    Return on Assets

    n/a
    		 -39.47%

    Return on Invested Capital

    n/a
    		 -48.62%

    Revenue Per Employee

    n/a
    		 $825,110

    Profits Per Employee

    n/a
    		 $-479,670

    Employee Count

    n/a
    		 100

    Asset Turnover

    n/a
    		 0.68

    Inventory Turnover

    n/a
    		 0.58

    Taxes

    Income Tax

    n/a
    		 3.12M

    Effective Tax Rate

    n/a
    		 -6.95%

    Stock Price Statistics

    The stock price has increased by 79.45% in the last 52 weeks. The beta is 1.68, so G1 Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.68

    52-Week Price Change

    n/a
    		 79.45%

    50-Day Moving Average

    n/a
    		 5.75

    200-Day Moving Average

    n/a
    		 4.06

    Relative Strength Index (RSI)

    n/a
    		 84.39

    Average Volume (20 Days)

    n/a
    		 2,229,441

    Income Statement

    In the last 12 months, G1 Therapeutics had revenue of 82.51M and earned -47.97M in profits. Earnings per share was -0.93.

    Revenue

    n/a
    		 82.51M

    Gross Profit

    n/a
    		 75.32M

    Operating Income

    n/a
    		 -39.53M

    Net Income

    n/a
    		 -47.97M

    EBITDA

    n/a
    		 -39.01M

    EBIT

    n/a
    		 -34.81M

    Earnings Per Share (EPS)

    n/a
    		 -0.93
    Full Income Statement

    Balance Sheet

    The company has 32.28M in cash and 57.17M in debt, giving a net cash position of -24.89M.

    Cash & Cash Equivalents

    n/a
    		 32.28M

    Total Debt

    n/a
    		 57.17M

    Net Cash

    n/a
    		 -24.89M

    Retained Earnings

    n/a
    		 -779.99M

    Total Assets

    n/a
    		 98.69M

    Working Capital

    n/a
    		 55.42M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -38.34M and capital expenditures 0, giving a free cash flow of -38.34M.

    Operating Cash Flow

    n/a
    		 -38.34M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -38.34M

    FCF Per Share

    n/a
    		 -0.74
    Full Cash Flow Statement

    Margins

    Gross margin is 91.28%, with operating and profit margins of -47.91% and -58.13%.

    Gross Margin

    n/a
    		 91.28%

    Operating Margin

    n/a
    		 -47.91%

    Pretax Margin

    n/a
    		 -54.36%

    Profit Margin

    n/a
    		 -58.13%

    EBITDA Margin

    n/a
    		 -47.28%

    EBIT Margin

    n/a
    		 -47.91%

    FCF Margin

    n/a
    		 -46.46%

    Dividends & Yields

    GTHX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -30.4%

    FCF Yield

    n/a
    		 -24.3%
    Dividend Details

    Analyst Forecast

    The average price target for GTHX is $3, which is -58.1% lower than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 -58.1%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -8.17

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist